104 related articles for article (PubMed ID: 38944863)
1. Response to Letter to Editor on "Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission".
Pasta A; Calabrese F; Bodini G
J Gastrointestin Liver Dis; 2024 Jun; 33(2):281. PubMed ID: 38944863
[No Abstract] [Full Text] [Related]
2. Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission.
Bodini G; Ghezzi A; Pasta A; Marabotto E; Calabrese F; Facchini C; Demarzo MG; Giannini EG
J Gastrointestin Liver Dis; 2023 Dec; 32(4):438-443. PubMed ID: 38147604
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Potential of
Oh GM; Moon W; Seo KI; Jung K; Kim JH; Kim SE; Park MI; Park SJ
Korean J Gastroenterol; 2021 Jan; 77(1):12-21. PubMed ID: 33361702
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
Burri E; Beglinger C; von Felten S; Lehmann FS
Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
[TBL] [Abstract][Full Text] [Related]
5. Review article: faecal calprotectin and histologic remission in ulcerative colitis.
D'Amico F; Bonovas S; Danese S; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2020 Apr; 51(7):689-698. PubMed ID: 32048751
[TBL] [Abstract][Full Text] [Related]
6. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
[TBL] [Abstract][Full Text] [Related]
7. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
[TBL] [Abstract][Full Text] [Related]
8. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial.
Langhorst J; Boone J; Lauche R; Rueffer A; Dobos G
J Crohns Colitis; 2016 Jul; 10(7):786-94. PubMed ID: 26874351
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
11. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
13. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
Reinisch W; Bressler B; Curtis R; Parikh A; Yang H; Rosario M; Røseth A; Danese S; Feagan B; Sands BE; Ginsburg P; Dassopoulos T; Lewis J; Xu J; Wyant T
Inflamm Bowel Dis; 2019 Mar; 25(4):803-810. PubMed ID: 30295811
[TBL] [Abstract][Full Text] [Related]
14. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
15. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis.
Önal İK; Beyazit Y; Şener B; Savuk B; Özer Etık D; Sayilir A; Öztaş E; Torun S; Özderın Özın Y; Tunç Demırel B; Ülker A; Dağli Ü
Turk J Gastroenterol; 2012; 23(5):509-14. PubMed ID: 23161295
[TBL] [Abstract][Full Text] [Related]
16. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission.
Kawashima K; Oshima N; Kishimoto K; Kataoka M; Fukunaga M; Kotani S; Sonoyama H; Oka A; Mishima Y; Kazumori H; Ishikawa N; Araki A; Ishihara S
Inflamm Bowel Dis; 2023 Mar; 29(3):359-366. PubMed ID: 35583193
[TBL] [Abstract][Full Text] [Related]
17. Utility of Escherichia coli Nissle in maintaining disease remission in inflammatory bowel disease.
Buldukoglu OC
J Gastrointestin Liver Dis; 2024 Jun; 33(2):280-281. PubMed ID: 38944860
[No Abstract] [Full Text] [Related]
18. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
Yamamoto T; Shiraki M; Bamba T; Umegae S; Matsumoto K
Int J Colorectal Dis; 2014 Apr; 29(4):485-91. PubMed ID: 24343276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
